Recommended dose of ROZLYTREK for adults is 600 mg orally once daily, with or without food 1
Temporary interruption, dose reduction, or discontinuation of treatment with ROZLYTREK may help manage adverse reactions 1
a For subsequent modifications, permanently discontinue
ROZLYTREK in patients who are unable to tolerate ROZLYTREK after 2
bLevel of severity as defined by National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE v4.0).
- Dose interruptions due to
adverse reactions occurred in 46% of patients. The most frequent
adverse reactions (≥2%) that resulted in interruption were
increased blood creatinine (4%), fatigue (3.7%), anemia (3.1%),
diarrhea (2.8%), pyrexia (2.8%), dizziness (2.5%), dyspnea (2.3%),
nausea (2.3%), pneumonia (2.3%), cognitive disorder (2%), and
ALT=alanine aminotransferase; AST=aspartate aminotransferase; NTRK=neurotrophic tyrosine receptor kinase; ULN=upper limit of normal.